Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Rare Disease. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, glucagon, needles, and other chronic diseases. The Rare Disease segment offers products in the areas of haemophilia, blood disorders, endocrine disorders, growth disorders, and hormone replacement therapy. The company has a collaboration agreement with Gilead Sciences, Inc.; and research collaboration with Novo Nordisk to discover cell-specific carriers of nucleic acid therapeutics. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.

Novo Nordisk A/S

Net Sales

Net Sales %Chg

Net Sales Common Size

Cost of Goods Sold

Cost of Goods Sold %Chg

Cost of Goods Sold Common Size

Gross Profit

Gross Profit %Chg

Gross Profit Common Size

Sales and Distribution Costs

Sales and Distribution Costs %Chg

Sales and Distribution Costs Common Size

Research and Development Costs

Research and Development Costs %Chg

Research and Development Costs Common Size

Administrative Costs

Administrative Costs %Chg

Administrative Costs Common Size

Other Operating Income and Expenses

Other Operating Income and Expenses %Chg

Other Operating Income and Expenses Common Size

Non-Recurring Income from the Initial Public Offering of NNIT a/S

Non-Recurring Income from the Initial Public Offering of NNIT a/S %Chg

Non-Recurring Income from the Initial Public Offering of NNIT a/S Common Size

Operating Profit

Operating Profit %Chg

Operating Profit Common Size

Financial Income

Financial Income %Chg

Financial Income Common Size

Financial Expenses

Financial Expenses %Chg

Financial Expenses Common Size

Profit Before Income Taxes

Profit Before Income Taxes %Chg

Profit Before Income Taxes Common Size

Income Taxes

Income Taxes %Chg

Income Taxes Common Size

Net Profit

Net Profit %Chg

Net Profit Common Size

Basic Earnings per Share

Basic Earnings per Share %Chg

Basic Earnings per Share Common Size

Diluted Earnings per Share

Diluted Earnings per Share %Chg

Diluted Earnings per Share Common Size

Total Revenues

Total Revenues %Chg

Total Revenues Common Size

Cost of Sales

Cost of Sales %Chg

Cost of Sales Common Size

Gross Profit Margin

Gross Profit Margin %Chg

Gross Profit Margin Common Size

Selling, General & Administrative Expenses

Selling, General & Administrative Expenses %Chg

Selling, General & Administrative Expenses Common Size

Research & Development Expenses

Research & Development Expenses %Chg

Research & Development Expenses Common Size

Other Operating Expenses

Other Operating Expenses %Chg

Other Operating Expenses Common Size

Operating Margin

Operating Margin %Chg

Operating Margin Common Size

Interest and Investment Income

Interest and Investment Income %Chg

Interest and Investment Income Common Size

Interest Expense

Interest Expense %Chg

Interest Expense Common Size

Total Non-Operating Income

Total Non-Operating Income %Chg

Total Non-Operating Income Common Size

Income Before Provision for Income Taxes

Income Before Provision for Income Taxes %Chg

Income Before Provision for Income Taxes Common Size

Provision for Income Taxes

Provision for Income Taxes %Chg

Provision for Income Taxes Common Size

Consolidated Net Income

Consolidated Net Income %Chg

Consolidated Net Income Common Size

Net Income Attributable to Common Shareholders

Net Income Attributable to Common Shareholders %Chg

Net Income Attributable to Common Shareholders Common Size

Basic EPS

Basic EPS %Chg

Basic EPS Common Size

Diluted EPS

Diluted EPS %Chg

Diluted EPS Common Size

Basic Weighted Average Shares Outstanding

Revenue

EBIT

EBITDA

CapEx

Net Interest Income

Assets

Adjusted EBITDA

Adjusted Net Income

Net Revenue

Net Income

Average Assets

Adjusted EBIT

Adjusted Revenue

Adjusted EBT

Adjusted Funds From Operations

Income Statement	Jun '25	Dec '24	Jun '24	Dec '23	Jun '23	Dec '22
Total Revenues	154,944	156,994	133,409	124,594	107,667	93,658
Total Revenues %Chg	16.1%	26%	23.9%	33%	29.3%	26.6%
Net Sales
Cost of Sales	25,736	24,332	20,190	19,727	16,038	15,462
Cost of Goods Sold
Gross Profit	129,208	132,662	113,219	104,867	91,629	78,196
Gross Profit
Gross Profit Margin	83.4%	84.5%	84.9%	84.2%	85.1%	83.5%
Selling, General & Administrative Expenses	34,961	36,873	30,504	32,701	28,897	27,700
Sales and Distribution Costs
Administrative Costs
Research & Development Expenses	21,998	23,290	24,772	18,588	13,855	13,718
Research and Development Costs
Other Operating Expenses	9	1,940	163	-101	-18	-493
Other Operating Income and Expenses
Non-Recurring Income from the Initial Public Offering of NNIT a/S
Operating Profit	72,240	70,559	57,780	53,679	48,895	37,271
Operating Profit
Operating Margin	46.6%	44.9%	43.3%	43.1%	45.4%	39.8%
Interest and Investment Income	8,739	3,092	3,106	2,374	571	-1,627
Financial Income
Interest Expense	-10,141	-3,710	-3,636	-370	-475	-1,296
Financial Expenses
Total Non-Operating Income	-1,402	-618	-530	2,004	96	-2,923
Income Before Provision for Income Taxes	70,838	69,941	57,250	55,683	48,991	34,348
Profit Before Income Taxes
Provision for Income Taxes	15,301	14,410	11,793	11,242	9,749	6,351
Income Taxes
Consolidated Net Income	55,537	55,531	45,457	44,441	39,242	27,997
Net Profit
Net Income Attributable to Common Shareholders	55,537	55,531	45,457	44,441	39,242	27,997
Net Profit
Basic EPS	12.5	12.5	10.2	9.9	8.7	6.2
Diluted EPS	12.5	12.5	10.2	9.9	8.7	6.2
Basic Weighted Average Shares Outstanding	4,443	4,453.2	4,456.6	4,470.9	4,495.1	4,512
Total Shares Outstanding	4,439.6	4,465	4,453.9	4,510	4,486.2	4,560
Diluted Weighted Average Shares Outstanding	4,446.5	4,456.7	4,469.7	4,484.5	4,505.4	4,530.3
EBITDA	80,903	77,907	69,539	59,196	52,791	41,347
Effective Tax Rate	21.6%	20.6%	20.6%	20.2%	19.9%	18.5%